CAMBRIDGE, MASSACHUSETTS — Skylark Bio announced that an independent Data Safety Monitoring Board (DSMB) has unanimously recommended advancing its investigational gene therapy, SKY-GJB2, into the next stage of the SONIX Phase 1/2 clinical trial. The decision follows a review of safety data from the first four children treated in the study, allowing researchers to begin enrolling younger participants....
Continue reading at Hearing Health Matters
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable clinical change yet — this is an early-phase (Phase 1/2) safety trial and no efficacy data are available; audiologists should monitor for future results.
Progression of GJB2-targeted gene therapy into expanded pediatric trials represents a potential paradigm shift toward biological hearing restoration for the most common form of genetic hearing loss.
- 01Skylark Bio's independent Data Safety Monitoring Board (DSMB) unanimously approved advancing the SKY-GJB2 gene therapy trial.
- 02The trial is the SONIX Phase 1/2 study targeting GJB2-related pediatric hearing loss.
- 03GJB2 mutations are the most common genetic cause of congenital hearing loss.
- 04DSMB advancement indicates no major safety signals in the initial cohort.
- 05Trial remains in early phase; efficacy and long-term outcomes are not yet established.
The independent DSMB unanimously recommended advancing SKY-GJB2 to the next stage of the SONIX Phase 1/2 trial.
press releasesupportedSKY-GJB2 is a gene therapy targeting pediatric hearing loss caused by GJB2 mutations.
press releasesupported- Publication type
- clinical_trial
- Evidence level
- 4
- Population
- Pediatric patients with hearing loss due to GJB2 gene mutations
- Intervention
- SKY-GJB2 gene therapy
Primary outcomes
Safety and tolerability; Advancement criteria for next trial stage
